6 results
The primary objective is to determine the effect of intravenously administered rhAPC on HDM-LPS induced allergic lung inflammation.
To demonstrate that treatment with drotrecogin alfa (activated) 24 mcg/kg/h administered as an intravenous infusion for 96 hours reduces 28 day all-cause mortality in adult patients with septic shock compared with placebo.
The primary objective is to determine the effect of locally administered rhAPC on LPS-induced lung inflammation and coagulation. By using measurements on cells harvested from bronchoalveolar lavage (BAL)-fluid and in BAL-fluid supernatants, we will…
To determine the influence of darolutamide on the pharmacokinetics of cabazitaxel compared to cabazitaxel alone in mCRPC patients.
To compare progression free survival (PFS) between treatment with docetaxel or cabazitaxel and darolutamide versus treatment with docetaxel or cabazitaxel in mCRPC patients.
To assess whether HBOT reduces pain, and improves physical functioning and QoL in breast cancer patients with late radiation toxicity.